Table 1.
Baseline patient demographics
| UK cohort |
AUS cohort |
|||
|---|---|---|---|---|
| ALL | GWAS | ALL | GWAS | |
| Total patients | 916 | 654 | 380 | 235 |
| One-year remission | ||||
| Yes | 562 (61.4) | 436 (66.7) | 244 (64.2) | 188 (80.0) |
| No | 342 (37.3) | 218 (33.3) | 96 (25.3) | 47 (20.0) |
| Not available (exclude) | 12 (1.3) | 0 | 40 (10.5) | 0 |
| Gender | ||||
| Male | 499 (54.5) | 346 (52.9) | 210 (55.3) | 120 (51.1) |
| Female | 417 (45.5) | 308 (47.1) | 170 (44.7) | 115 (48.9) |
| Age at treatment in years, mean (IQR) | 39 (23–53) | 39 (22–53) | 41 (25–55) | 43 (26–56) |
| Neurological impairment | ||||
| Yes | 69 (7.5) | 37 (5.7) | 9 (2.4) | 7 (3.0) |
| No | 847 (92.5) | 617 (94.3) | 264 (69.5) | 228 (97.0) |
| Not available (exclude) | 0 | 0 | 107 (28.2) | 0 |
| Number of seizures ever before treatment | ||||
| One or not available (exclude) | 2 (0.2) | 0 | 53 (13.9) | 0 |
| 2 | 113 (12.3) | 93 (14.2) | 88 (23.2) | 64 (27.2) |
| 3 | 88 (9.6) | 71 (10.9) | 40 (10.5) | 31 (13.2) |
| 4 | 67 (7.3) | 57 (8.7) | 25 (6.6) | 16 (6.8) |
| 5 | 35 (3.8) | 26 (4.0) | 12 (3.2) | 10 (4.3) |
| >5 | 611 (66.7) | 407 (62.2) | 162 (42.6) | 114 (48.5) |
| Epilepsy type | ||||
| Generalized | 140 (15.3) | 107 (16.4) | 73 (19.2) | 41 (17.4) |
| Focal | 647 (70.6) | 455 (69.6) | 273 (71.8) | 185 (78.7) |
| Unclassified | 125 (13.6) | 92 (14.1) | 18 (4.7) | 9 (3·8) |
| Not available | 4 (0·4) | 0 | 16 (4.2) | 0 |
| EEG results | ||||
| Normal/non-specific abnormality | 606 (66.2) | 431 (65.9) | 229 (60.3) | 152 (64.7) |
| Epileptiform abnormality | 238 (26.0) | 174 (26.6) | 142 (37.4) | 81 (34.5) |
| Not done | 72 (7.9) | 49 (7.5) | 9 (2.4) | 2 (0.9) |
| CT/MRI results | ||||
| Normal | 519 (56.3) | 381 (58.2) | 279 (73.4) | 185 (78.2) |
| Abnormal | 186 (20.3) | 119 (18.2) | 84 (22.1) | 46 (20.2) |
| Not done | 211 (23.0) | 154 (23.5) | 17 (4.5) | 4 |
| Initial AED treatment | ||||
| CBZ | 159 (17.4) | 107 (16.4) | 172 (45.3) | 111 (47.2) |
| Gabapentin (GBP) | 156 (17.0) | 105 (16.1) | 1 (0.3) | 0 |
| Levetiracetam (LEV) | 0 | 0 | 25 (6·6) | 18 (7·7) |
| Lamotrigine (LTG) | 208 (22.7) | 152 (23.2) | 21 (5.5) | 16 (6.8) |
| Phenytoin (PHT) | 0 | 0 | 14 (3.7) | 8 (3.4) |
| Zonisamide (ZNS) | 0 | 0 | 4 (1.1) | 3 (1.3) |
| Oxcarbazepine (OXC) | 99 (10.8) | 70 (10.7) | 0 | 0 |
| Topiramate (TPM) | 225 (24.6) | 165 (25.2) | 0 | 0 |
| Sodium valproate (VPS) | 69 (7.5) | 55 (8.4) | 141 (37.1) | 79 (33.6) |
| Not available | 0 | 0 | 2 (0.5) | 0 |
Values in the table are actual number with percentages in brackets. ALL refers to all patients recruited to the study, and GWAS to those patients included in the genome-wide association study.